Katana VentraIP

Melanocyte-stimulating hormone

The melanocyte-stimulating hormones, known collectively as MSH, also known as melanotropins or intermedins, are a family of peptide hormones and neuropeptides consisting of α-melanocyte-stimulating hormone (α-MSH), β-melanocyte-stimulating hormone (β-MSH), and γ-melanocyte-stimulating hormone (γ-MSH) that are produced by cells in the pars intermedia of the anterior lobe of the pituitary gland.

Synthetic analogues of α-MSH, such as afamelanotide (melanotan I; Scenesse), melanotan II, and bremelanotide (PT-141), have been developed and researched.

Biosynthesis[edit]

The various forms of MSH are generated from different cleavages of the proopiomelanocortin protein, which also yields other important neuropeptides like adrenocorticotropic hormone.[1]: 554  [2]


Melanocytes in skin make and secrete MSH in response to ultraviolet light, where it increases synthesis of melanin.[3]: 441  Some neurons in arcuate nucleus of the hypothalamus make and secrete α-MSH in response to leptin;[3]: 626 [4]: 419  α-MSH is also made and secreted in the anterior lobe of the pituitary gland.[5]: 1210 

(brand name Scenesse) has been approved for the treatment of erythropoietic protoporphyria in Europe and is also being investigated as a method of photoprotection in the treatment of polymorphous light eruption, actinic keratosis and squamous cell carcinoma (a form of skin cancer).[7]

Afamelanotide

An additional analogue called causes enhanced libido and erections in most male test subjects and arousal with corresponding genital involvement in most female test subjects.[8] Bremelanotide (formerly PT-141) which stemmed from melanotan II research is currently under development for its aphrodisiac effects. These effects are mediated by actions in the hypothalamus on neurons that express MC3 and MC4 receptors.

melanotan II

Synthetic analogues of α-MSH have been developed for human use. Two of the better known are afamelanotide (melanotan I) in testing by Clinuvel Pharmaceuticals and bremelanotide by Palatin Technologies. Others include modimelanotide and setmelanotide.

Melanocyte-inhibiting factor

Agouti-related peptide

Agouti signalling peptide

Nelson's syndrome

Millington GW (May 2006). "Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors". Clin. Exp. Dermatol. 31 (3): 407–12. :10.1111/j.1365-2230.2006.02128.x. PMID 16681590. S2CID 25213876.

doi

Millington GW (2007). . Nutr Metab (Lond). 4: 18. doi:10.1186/1743-7075-4-18. PMC 2018708. PMID 17764572.

"The role of proopiomelanocortin (POMC) neurones in feeding behaviour"

at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

Melanocyte-Stimulating+Hormones